Thanks Lightsup, meanwhile Arixtra continues to expand, sorry haven't signed up for the full article as yet:
Arixtra filed for acute treatment uses in Japan
07 April 2010
Ian Haydock
GlaxoSmithKline has made a regulatory submission in Japan for the approval of Arixtra (fondaparinux sodium) for the additional indications of treatment of acute pulmonary thromboembolism and acute deep vein thrombosis (DVT).
http://www.scripnews.com/researchdevelopment/Arixtra-filed-for-acute-treatment-uses-in-Japan-239304
reddy's analysis, page-31
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable